BOSCHEINEN, Oliver,DREYER, Matthias,HABERMANN, Paul,SCHAEFER, Hans-Ludwig,SOMMERFELD, Mark,LANGER, Thomas
申请号：
TN2015000053
公开号：
TN2015000053A1
申请日:
2015.02.18
申请国别(地区):
TN
年份:
2016
代理人:
摘要：
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.
